A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
296
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators